

Anna F Farago

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/570995/publications.pdf>

Version: 2024-02-01

58
papers

8,949
citations

136950

32
h-index

144013

57
g-index

58
all docs

58
docs citations

58
times ranked

10304
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. <i>Cancer Discovery</i> , 2022, 12, 1500-1517.	9.4	49
2	Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer. <i>Science Advances</i> , 2022, 8, eabn1229.	10.3	9
3	Phase I/II investigator-initiated study of olaparib and temozolomide in SCLC: Updated analysis and CNS outcomes.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8565-8565.	1.6	1
4	Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. <i>Clinical Cancer Research</i> , 2021, 27, 1695-1705.	7.0	19
5	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1253-1263.	1.6	74
6	A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. <i>Npj Precision Oncology</i> , 2021, 5, 74.	5.4	27
7	Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 5775.	12.8	59
8	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 271-282.	10.7	1,034
9	The Art of Oncology: COVID-19 Era. <i>Oncologist</i> , 2020, 25, 997-1000.	3.7	6
10	Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers. <i>Future Oncology</i> , 2020, 16, 417-425.	2.4	19
11	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 520-540.	1.1	119
12	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology</i> , The, 2020, 21, 531-540.	10.7	608
13	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100074.	1.1	10
14	Efficacy and safety of entrectinib in patients (pts) with <i>NTRK</i> -fusion positive (<i>NTRK</i> -fp) solid tumors: An updated integrated analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3605-3605.	1.6	33
15	Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded data set.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3610-3610.	1.6	11
16	Quality of life of adults and children with TRK fusion cancer treated with larotrectinib compared to the general population.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3614-3614.	1.6	2
17	CTNI-04. ACTIVITY OF LAROTRECTINIB IN TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTASES. <i>Neuro-Oncology</i> , 2020, 22, ii41-ii42.	1.2	1
18	Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. <i>Cancer Discovery</i> , 2019, 9, 1372-1387.	9.4	158

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. <i>Clinical Cancer Research</i> , 2019, 25, 6958-6966.	7.0	206
20	Identification of DHODH as a therapeutic target in small cell lung cancer. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	89
21	Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity. <i>Clinical Cancer Research</i> , 2019, 25, 6662-6670.	7.0	122
22	Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. <i>Journal of Thoracic Oncology</i> , 2019, 14, 835-843.	1.1	9
23	Unexpected Synergy Reveals New Therapeutic Strategy in SCLC. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 295-297.	8.7	17
24	<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. <i>Journal of Clinical Oncology</i> , 2019, 37, 278-285.	1.6	286
25	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. <i>Journal of Thoracic Oncology</i> , 2019, 14, 237-244.	1.1	241
26	Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). <i>Cancer Research</i> , 2019, 79, CT127-CT127.	0.9	57
27	Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2006-2006.	1.6	60
28	Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3017-3017.	1.6	25
29	Larotrectinib efficacy and safety in adult TRK fusion cancer patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3122-3122.	1.6	10
30	Efficacy of Larotrectinib in <i>TRK</i> Fusion-Positive Cancers in Adults and Children. <i>New England Journal of Medicine</i> , 2018, 378, 731-739.	27.0	2,036
31	Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. <i>Cancer Discovery</i> , 2018, 8, 600-615.	9.4	157
32	Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an <i>NTRK</i> Gene Fusion. <i>JCO Precision Oncology</i> , 2018, 2018, 1-12.	3.0	112
33	Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	3.0	86
34	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	3.0	17
35	Current standards for clinical management of small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 69-79.	2.8	161
36	Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <i>KRAS</i> -Mutant Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2018, 8, 1598-1613.	9.4	71

#	ARTICLE	IF	CITATIONS
37	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1530-1538.	1.1	62
38	Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8571-8571.	1.6	4
39	Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8573-8573.	1.6	1
40	ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS8587-TPS8587.	1.6	4
41	Targeting TRK family proteins in cancer. , 2017, 173, 58-66.		217
42	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017, 7, 400-409.	9.4	647
43	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. <i>Npj Precision Oncology</i> , 2017, 1, 5.	5.4	49
44	Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care. <i>Cell Reports</i> , 2017, 21, 3298-3309.	6.4	157
45	Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancerâ€“Transformed <i>EGFR</i> Mutant Nonâ€“Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-7.	3.0	8
46	Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 550-559.	2.8	68
47	Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Nonâ€“Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	3.0	158
48	Clinicopathologic features of non-small cell lung cancer (NSCLC) harboring an <i>NTRK</i> gene fusion.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11580-11580.	1.6	2
49	The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA2501-LBA2501.	1.6	27
50	The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA2501-LBA2501.	1.6	63
51	<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Nonâ€“Small Cell Lung Cancer: A Retrospective Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 4585-4593.	7.0	977
52	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	1.1	156
53	Frequency and spectrum of ROS1 resistance mutations in ROS1-positive lung cancer patients progressing on crizotinib.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9072-9072.	1.6	12
54	Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1670-1674.	1.1	197

#	ARTICLE	IF	CITATIONS
55	Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1288-96.	7.1	110
56	STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.. Journal of Clinical Oncology, 2015, 33, 2596-2596.	1.6	22
57	A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.. Journal of Clinical Oncology, 2015, 33, TPS2624-TPS2624.	1.6	6
58	Clinical implementation of anchored multiplex PCR with targeted next-generation sequencing for detection of ALK, ROS1, RET and NTRK1 fusions in non-small cell lung carcinoma.. Journal of Clinical Oncology, 2015, 33, 8095-8095.	1.6	1